254 related articles for article (PubMed ID: 38248108)
1. Counselling Framework for Germline
Wong SM; Apostolova C; Eisenberg E; Foulkes WD
Curr Oncol; 2024 Jan; 31(1):350-365. PubMed ID: 38248108
[TBL] [Abstract][Full Text] [Related]
2. Timing of genetic testing in BRCA1/2 and PALB2-Associated breast cancer: Preoperative result disclosure increases uptake of risk-reducing mastectomy and reduces unnecessary exposure to radiotherapy.
Apostolova C; Ferroum A; Alhassan B; Prakash I; Basik M; Boileau JF; Martel K; Meterissian S; Villareal Corpuz V; Wong N; Foulkes WD; Wong SM
Eur J Surg Oncol; 2024 Jun; 50(6):108324. PubMed ID: 38636249
[TBL] [Abstract][Full Text] [Related]
3. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
Yamauchi H; Nakagawa C; Kobayashi M; Kobayashi Y; Mano T; Nakamura S; Arai M
Breast Cancer; 2018 Mar; 25(2):141-150. PubMed ID: 29019095
[TBL] [Abstract][Full Text] [Related]
5. Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers.
Chai X; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Tung N; Weitzel JN; Couch FJ; Hulick PJ; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Blum JL; Domchek SM; Chen J; Rebbeck TR
Breast Cancer Res Treat; 2014 Nov; 148(2):397-406. PubMed ID: 25311111
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
Manchanda R; Patel S; Gordeev VS; Antoniou AC; Smith S; Lee A; Hopper JL; MacInnis RJ; Turnbull C; Ramus SJ; Gayther SA; Pharoah PDP; Menon U; Jacobs I; Legood R
J Natl Cancer Inst; 2018 Jul; 110(7):714-725. PubMed ID: 29361001
[TBL] [Abstract][Full Text] [Related]
7. Differences among a Portuguese cohort of BRCA pathogenic/likely pathogenic variants carriers choosing risk-reducing mastectomy or intensive breast surveillance.
Torres S; Peleteiro B; Magalhães A; Garrido L; Costa S; Fougo JL
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7529-7538. PubMed ID: 36971799
[TBL] [Abstract][Full Text] [Related]
8. Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in
Yadav S; Boddicker NJ; Na J; Polley EC; Hu C; Hart SN; Gnanaolivu RD; Larson N; Holtegaard S; Huang H; Dunn CA; Teras LR; Patel AV; Lacey JV; Neuhausen SL; Martinez E; Haiman C; Chen F; Ruddy KJ; Olson JE; John EM; Kurian AW; Sandler DP; O'Brien KM; Taylor JA; Weinberg CR; Anton-Culver H; Ziogas A; Zirpoli G; Goldgar DE; Palmer JR; Domchek SM; Weitzel JN; Nathanson KL; Kraft P; Couch FJ
J Clin Oncol; 2023 Mar; 41(9):1703-1713. PubMed ID: 36623243
[TBL] [Abstract][Full Text] [Related]
9. Trends and timing of risk-reducing mastectomy uptake in unaffected BRCA1 and BRCA2 carriers in Slovenia.
Ložar T; Žgajnar J; Perhavec A; Blatnik A; Novaković S; Krajc M
Eur J Surg Oncol; 2021 Aug; 47(8):1900-1906. PubMed ID: 33812767
[TBL] [Abstract][Full Text] [Related]
10. BRCA1/2 mutation carriers & risk reducing mastectomy: Who undergoes surgery and potential benefits.
Record SM; Thomas SM; Ntowe K; Chiba A; Plichta JK
Am J Surg; 2024 Jan; 227():146-152. PubMed ID: 37827871
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer.
Wei X; Sun L; Slade E; Fierheller CT; Oxley S; Kalra A; Sia J; Sideris M; McCluggage WG; Bromham N; Dworzynski K; Rosenthal AN; Brentnall A; Duffy S; Evans DG; Yang L; Legood R; Manchanda R
JAMA Netw Open; 2024 Feb; 7(2):e2355324. PubMed ID: 38334999
[TBL] [Abstract][Full Text] [Related]
12. Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.
Gamble C; Havrilesky LJ; Myers ER; Chino JP; Hollenbeck S; Plichta JK; Kelly Marcom P; Shelley Hwang E; Kauff ND; Greenup RA
Ann Surg Oncol; 2017 Oct; 24(11):3116-3123. PubMed ID: 28699130
[TBL] [Abstract][Full Text] [Related]
13. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
Cragun D; Weidner A; Tezak A; Clouse K; Pal T
Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
[TBL] [Abstract][Full Text] [Related]
14. Surgical Decision Making in Genetically High-Risk Women: Quantifying Postoperative Complications and Long-Term Risks of Supplemental Surgery After Risk-Reducing Mastectomy.
Apostolova C; Ferroum A; Alhassan B; Prakash I; Viezel-Mathieu A; Basik M; Boileau JF; Meterissian S; Wong N; Foulkes WD; Wong SM
Ann Surg Oncol; 2024 Jan; 31(1):356-364. PubMed ID: 37838650
[TBL] [Abstract][Full Text] [Related]
15. Specialty Care and Counselling about Hereditary Cancer Risk Improves Adherence to Cancer Screening and Prevention in Newfoundland and Labrador Patients with
Roebothan A; Smith KN; Seal M; Etchegary H; Dawson L
Curr Oncol; 2023 Oct; 30(10):9367-9381. PubMed ID: 37887578
[TBL] [Abstract][Full Text] [Related]
16. Bilateral Prophylactic Nipple-Sparing Mastectomy: Analysis of the Risk-Reducing Effect in BRCA1/2 Mutation Carriers.
Stanek K; Zimovjanova M; Suk P; Jonas F; Zimovjanova A; Molitor M; Mestak O
Aesthetic Plast Surg; 2022 Apr; 46(2):706-711. PubMed ID: 34342702
[TBL] [Abstract][Full Text] [Related]
17. Risk-reducing surgery in BRCA1/BRCA2 mutation carriers: Are there factors associated with the choice?
Manoukian S; Alfieri S; Bianchi E; Peissel B; Azzollini J; Borreani C
Psychooncology; 2019 Sep; 28(9):1871-1878. PubMed ID: 31264307
[TBL] [Abstract][Full Text] [Related]
18. Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negative breast cancer patients.
Wu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
Breast Cancer Res Treat; 2020 Feb; 179(3):605-614. PubMed ID: 31768816
[TBL] [Abstract][Full Text] [Related]
19. Mastectomy with Reconstruction Including Robotic Endoscopic Surgery (MARRES): a prospective cohort study of the Korea Robot-Endoscopy Minimal Access Breast Surgery Study Group (KoREa-BSG) and Korean Breast Cancer Study Group (KBCSG).
Ryu JM; Lee J; Lee J; Ko B; Kim JH; Shin H; Park HS;
BMC Cancer; 2023 Jun; 23(1):571. PubMed ID: 37344780
[TBL] [Abstract][Full Text] [Related]
20. Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis.
Metcalfe K; Huzarski T; Gronwald J; Kotsopoulos J; Kim R; Moller P; Pal T; Aeilts A; Eisen A; Karlan B; Bordeleau L; Tung N; Olopade O; Zakalik D; Singer CF; Foulkes W; Couch F; Neuhausen SL; Eng C; Sun P; Lubinski J; Narod SA;
Br J Cancer; 2024 Feb; 130(2):269-274. PubMed ID: 38030749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
